Valeritas' V-Go Wearable Insulin delivery device is now available in Australia through the company's previously disclosed exclusive distribution agreement with AMSL Diabetes.
Image: Valeritas launches new insulin delivery device. Photo: Courtesy of Michaela Kobyakov/FreeImages.com
Valeritas CEO, John Timberlake said: “We are pleased to announce V-Go Wearable Insulin Delivery device is now available for patients with type 2 diabetes in Australia. Australia is the second and largest country outside of the US in which our flagship product V-Go has been launched, and we are excited V-Go will be demonstrated to physicians and patients during the Australia Diabetes Society meeting in Adelaide this week.”
Through the distribution agreement, Valeritas will retain responsibility for product development, regulatory approval, quality management, and manufacturing while AMSL Diabetes will be responsible for sales, marketing, customer support, and distribution activities in Australia.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.
Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots.
V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.
Source: Company Press Release